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The mechanisms of chohnergic stimulation of gastrin cells were studied in the rat pancreatic ell line B6 RIN. Carbachol induced an increase in 
intracelhtlar Ca2+ and stimulated gastrin release in a dose-dependent manner over the range 10-“-107 M. These effects were completely abolished 
by atropine, suggesting the implication of muscarinic holinergic receptors. The binding properties of these receptors were investigated. [N-Methyl- 
3H]scopolamine (PH]NMS) binding on cell homogenates was time-dependent, saturable and consistent with a single high-affinity binding class 
(& = 39.5 pM, and B-= 7.9 fmol/mg DNA). Carbachol competitively inhibited PH]NMS binding. The potency of inhibition of PI-IINMS binding 
by subtype selective antagonists was hexahydrodifenidol> pirenzepine > AF-DX 116. These results suggest he M, muscarinic receptors may be 
involved in the carbachol-induced gastrin release from B6 RIN cells. 
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1. INTRODUCTION 
Cholinergic agonists are strong stimulants of gastrin 
release in the rat and dog [l-3], presumably through 
binding to specific receptors on gastrin G-cells. Such 
receptors have not been characterized so far on native 
G-cells because cell enrichment through the currently 
available methods does not reach homogeneity. To 
overcome this problem, we used a cell line derived from 
a radiation-induced insulin-producing rat tumor [4]. 
The B6 RIN cell line: (i) expresses the gastrin gene at 
high levels while the insulin, somatostatin and 
cholecystokinin genes are not expressed [5]; and (ii) 
secretes fully processed gastrin [5]. Although some 
reports suggest hat muscarinic receptors are expressed 
by RIN cell lines [6], no data are available on their bin- 
ding characteristics. These were investigated in the pre- 
sent study, as well as the functional relationship be- 
tween the occupation of muscarinic receptors and 
gastrin release. 
(St. Louis, USA). Pirenzepine (Gastrozepin) and AF-DX 116 were 
kindly provided by Dr. Waelbroeck (Brussels, Belgium). Hex- 
ahydrodifenidol was obtained from Dr. Lambrecht (Frankfurt, 
FRG). 
2.2. Cell culture 
B6 RIN cells were grown in RPM1 medium supplemented with 10% 
heat-inactivated fetal calf serum (PBS Orgenics, Illkirch, France), 2 
mM glutamine and antibiotics (100 IU/ml penicillin + 50 Ic.g/ml 
streptomycin) in a 5% COs/95% air incubator at 37°C. Cells were 
routinely transferred every 3 days in 4 ~01s. of fresh medium. 
2.3. Gastrin release 
Confluent cells (4 x lo6 cells/35 mm well) were incubated in a total 
volume of 2 ml RPM1 medium containing 0.5% bovine serum 
albumin (BSA) and the indicated effecters for 2 h at 37°C. The in- 
cubation medium was collected, and cells were disrupted in boiling 
water and centrifuged. Immunoreactive gastrin was measured in 
supernatants and in cell extracts with a radioimmunoassay previously 
described in a study on gastrin in rats [7]. 
2.4. Binding studies 
2. MATERIALS AND METHODS 
2.1. Materials 
[‘HINMS (74 Ci/mmol) was purchased from Amersham (Les Ullis, 
France). Atropine sulfate and carbachol were from Sigma Chemicals 
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Cells were harvested from culture flasks with trypsin/EDTA 
(O.O5~o/O.O2’?‘o) in Hanks medium, lysed in hypotonic 1 mM 
NaHCOs (pH 7.0) and quickly frozen in liquid nitrogen. After thaw- 
ing, the lysate was homogenized in 20 mM Tris-HCl buffer (pH 7.5) 
enriched with 0.25 M sucrose and directly used for binding studies. 
Homogenates (120-150 pg protein) were incubated for 2 h at 25°C in 
1.2 ml of incubation buffer (75 mM sodium phosphate buffer, 3 mM 
MgClz, 1.5% BSA, pH 7.4), and the indicated concentrations of 
[3H]NMS, carbachol or antagonists. The reaction was stopped by 
rapid filtration on GF/C glass-fiber filters (Whatman, Maidstone, 
UK), followed by 4 rinsing cycles with 2 ml of ice-cold 50 mM 
phosphate buffer (pH 7.4). The filters were dried and the radioactivity 
was counted by liquid scintillation. Non-specific binding was defined 
as binding in the presence of 1 PM atropine. Competition curves were 
analyzed by computer fitting to a model of one or two classes of bind- 
ing sites using the LIGAND program [8]. The dissociation constants 
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Fig. 1. Effects of carbachol on gastrin release (upper panel) and on 
gastrin intracellular contents (lower panel). Cells were incubated for 
2 h at 37°C with the indicated concentrations of carbachol or with 1 
mM carbachol plus 1 CM atropine. The results are the mean * SEM 
of 8 separate xperiments. Asterisks indicate statistically significant 
variations (P<O.O5) from control values. 
of the analogues tested were corrected according to the method of 
Cheng and Prussof [9]. DNA was determined using the method of 
Labarca and Paigen [lo]. 
2.5. Determination of /Cd+ ji 
[Ca*+ ]i was measured as described in [6]. Briefly, cells were in- 
cubated for 30 min at 37°C in RPM1 medium containing 1 Vo fetal calf 
serum, 10 mM Hepes and 1 CM furaZ/AM under continuous tirring. 
After this loading period, cells were washed and resuspended in a 
modified Krebs Ringer bicarbonate buffer. The fluorescence signal of 
fura was recorded with excitation and emission at 340 and 510 nm, 
respectively. 
3. RESULTS 
Carbachol produced a dose-dependent increase in 
gastrin release from B6 RIN cells over the range 10e5- 
lo- 3 M(Fig. 1, upper panel). Maximal gastrin release 
was observed with 1 mM carbachol(25.7 f 1.5 pg/106 
cells/2 h compared to 13.7 rf: 1.3 pg/106 cells/2 h basal 
release, P<O.O5, n = 8). Carbachol-stimulated gastrin 
release was linked to a decrease in intracellular gastrin 
content (Fig. 1, lower panel), from 70.0 + 7.8 pg/106 
cells in control cells to 38.1 + 3.3 pg/106 cells in 1 mM 
carbachol-pretreated cells (PC 0.05, n = 8). Incubation 
of the cells in the presence of the muscarinic antagonist 
atropine did not alter basal gastrin release but com- 
pletely inhibited carbachol-stimulated gastrin release. 
Muscarinic cholinergic receptors on B6 RIN cell 
homogenates were characterized using the reversible 
cholinergic antagonist [3H]NMS. [3H]NMS binding 
was measured at 25°C for 2 h, which corresponds to 
equilibrium binding conditions for all tested concentra- 
tions of [3H]NMS (not shown). Fig. 2, left, shows that 
binding of [3H]NMS in the presence of 1 PM atropine 
was linearly related to tracer concentration. Specific 
binding, determined after substraction of binding in the 
presence of atropine, was saturable, a plateau being 
achieved for a tracer concentration of 200 pM. Scat- 
chard analysis of the specific binding curve (Fig. 2, 
right) provided a mean equilibrium dissociation con- 
stant (Kd) of 39.5 pM and a maximal binding level 
(Bmax) of 7.9 fmol/mg DNA. The linear nature of the 
Scatchard plot (r = 0.966) indicates that binding of the 
antagonist is to a single class of high affinity sites. 
Cholinergic agonist interaction with B6 RIN cell 
muscarinic receptors was also studied using [3H]NMS 
binding (Fig. 3). Carbachol competitively inhibited bin- 
ding of [3H]NMS. Computer analysis of the displace- 
ment curve suggested high (& = 2.1 PM) and low (& 
= 16.2 PM) affinity sites for carbachol, that applied to 
26 and 74% of the receptor population, respectively. 
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Fig. 2. Binding of [3H]NMS to B6 RIN cell homogenates. (Left) Experimental data. Homogenates were incubated for 2 h at 25°C with indicated 
concentrations of [‘H]NMS either with or without 1 FM atropine. q , specific binding; n , non-specific binding. The results are the means of 3 
experiments performed in duplicate. (Right) Scatchard analysis of specific binding curve shown on the left. 
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Fig. 3. Carbachol inhibition of [3H]NMS binding to B6 RIN cell 
homogenates. Homogenates were incubated for 2 h at 25°C in the 
presence of 150 pM [3H]NMS and of increasing concentrations of car- 
bachol. The data are expressed as the percentage of [‘H]NMS 
specifically bound (means of 3 experiments performed in duplicate). 
Competition studies of [3H]NMS binding with Ml, MZ 
and M3 muscarinic antagonists yielded the following 
order of potency: hexahydrodifenidol (Ki = 23.6 nM) 
> pirenzepine (Ki = 166.3 nM) > AF-DX 116 (Ki = 
1431 nM) (Fig. 4), consistent with the presence of M3 
subtype receptors on B6 RIN cells. 
Carbachol caused a biphasic increase in [Ca2+]i, 
which peaked promptly after addition of the 
secretagogue and then returned to a lower plateau 
value. This effect was dose-dependent over the range 
lo-’ - lo- 3M, and completely abolished by the addi- 
tion of 100 PM atropine (Fig. 5). 
4. DISCUSSION 
Only one study, based on the isolated rat stomach 
preparation, bore on the muscarinic receptor subtypes 
involved in the cholinergic stimulation of gastrin release 
[ 111. High affinity receptors were indirectly evidenced, 
and found to be sensitive to the Mi antagonist 
pirenzepine, with an apparent inhibition constant of 2 
nM. However, other studies have shown that 
CAntagonist] (log M 1 
Fig. 4. Inhibition of [‘HINMS binding to B6 RIN cell homogenates by 
pirenzepine (A ), AF-DX 116 (A) and hexahydrodifenidol (m). 
Homogenates were incubated for 2 h at 25°C in the presence of 150 
pM [3HJNMS and of increasing concentrations of antagonists. The 
data are expressed as in Fig. 3 and are the means of 3 experiments per- 
formed in duplicate. 
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Fig. 5. Effects of carbachol on cytosolic free calcium in furat-loaded 
B6 RIN cells. (A) Dose-dependent effect of carbachol. (B) Inhibition 
of carbachol-induced calcium increase by 100 @I atropine. Recor- 
dings are representative of 3 separate xperiments. 
cholinergic stimulation of gastrin release in rats may 
result from inhibition of the G-cell restraint by antral 
somatostatin cells [12]. Conclusions drawn from phar- 
macological experiments in the isolated rat stomach 
may thus fall short of specifically applying to the 
presumptive muscarinic receptors on G-cells. 
Since (i) 5 subtypes of muscarinic receptors were 
recently cloned [ 131, and (ii) various antagonists were 
developed, a reappraisal of the muscarinic receptor sub- 
type(s) mediating the response of G-cells to cholinergic 
agents was required. The B6 RIN cell line was used 
here: Carbachol increased gastrin release from these 
cells, and correlatively reduced the cellular gastrin con- 
tents, suggesting that it did not increase gastrin syn- 
thesis to any measurable xtent in the present short term 
experiments. Carbachol induced a definite increase of 
cytosolic free calcium. Gastrin release, depletion of in- 
tracellular gastrin and rise of calcium were all abolished 
by atropine. 
Pharmacological characterization of the muscarinic 
receptors with specific antagonists of receptor subtypes 
showed that the lowest Ki value of [3H]NMS binding 
was obtained for the M3 antagonist hexahydrodifeni- 
dol, the inhibition constant being 10 times lower than 
that of the Mi antagonist pirenzepine, and lOO-fold 
lower than that of the MZ antagonist AF-DX 116. This 
order of potency is similar to that observed with the 
muscarinic antagonists pirenzepine, AF-DX 116 and 
hexahydrosiladifenidol (MS antagonist) in Xenopus 
oocytes and in NG108-15 neuroblastoma-glioma hybrid 
cells transfected with cDNA encoding the muscarinic 
M3 subtype receptor [14,15]. Similar results were also 
reported using 4-DAMP as M3 subtype receptor an- 
tagonist in SH-SYSY neuroblastoma cells that are 
thought to possess M3 muscarinic receptors [5]. Taken 
together, these data suggest the presence of MJ 
muscarinic receptors on B6 RIN cells. 
Using RNA blot hybridization analysis with specific 
probes, M3 receptors have been demonstrated in 
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cerebral cortex [ 17,181, lachrymal and parotid glands 
[ 191, and intestinal smooth muscle tissue [19]. Our 
study demonstrates for the first time that muscarinic M3 
subtype receptors are also localized on an endocrine cell 
line, thus extending the distribution spectrum of M3 
subtype receptors. 
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